Effects of Gemfibrozil on Lipids and Haemostasis after Myocardial Infarction

Summary

The effects of gemfibrozil on haemostatic variables were studied in 43 survivors of myocardial infarction with serum triglycerides (TG) ≥2 mmol/1 2 weeks prior to randomization. The study was double-blind, placebo-controlled and stratified for chronic betablockade. Twenty-two individuals were given gemfibrozil 600 mg twice daily and 21 individuals received matching placebo. After 8 weeks the TG level was unchanged in the placebo group, whereas a 44% reduction was noted in the gemfibrozil group (p <0.0001). Fibrinogen increased in both groups, while bleeding time and platelet count were unchanged. Clotting factor VH-phospholipid complex decreased in both groups, but the change was more marked and attained statistical significance only in the gemfibrozil group (60% reduction, p <0.01). By DDAVP-stimulated D-Dimer agglutination test 8 in 21 patients in the placebo group (38%) still had reduced fibrinolytic capacity versus none in the gemfibrozil group (p = 0.001). Thus, in this study, gemfibrozil improved reduced fibrinolytic capacity and may have reduced hypercoagulability by lowering the clotting factor VH-phospholipid complex.

• References

• 1 Carlson LA, Åberg H. Serum triglycerides – An independent risk factor for myocardial infarction but not for angina pectoris. N Engl J Med 1985; 312: 1127
• 2 Simpson HC R, Meade TW, Stirling Y, Mann JI, Chakrabarti R, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; i: 786-790
• 3 Andersen P, Arnesen H, Hjermann I. Hyperlipoproteinaemia and reduced fibrinolytic activity in healthy coronary high-risk men. Acta Med Scand 1981; 209: 199-202
• 4 Dalaker K, Smith P, Arnesen H, Prydz H. Factor Vll-phospholipid complex in male survivors of acute myocardial infarction. Acta Med Scand 1987; 222: 111-116
• 5 Andersen P, Nilsen DW T, Lyberg Beckmann S, Holme I, Hjermann I. Increased fibrinolytic potential after diet intervention in healthy coronary high-risk individuals. Acta Med Scand 1988; 223: 499-506
• 6 Kesaniemi YA, Grundy SM. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA 1984; 251: 2241-2246
• 7 Frick MH. et al Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-1245
• 8 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
• 9 Dalaker K, Janson TL, Hohnsen B, Skartlien AH, Prydz H. A simple method for determination of the factor Vll-phospholipid complex using Normotest. Thromb Res 1987; 47: 287-293
• 10 Nilsson IM, Olow B. Fibrinolysis induced by streptokinase in man. Acta Chir Scand 1962; 123: 247-266
• 11 Seljeflot I, Arnesen H, Smith P, Andersen P. D-Dimer agglutination test in the evaluation of fibrinolytic capacity after stimulation with DDAVP. Fibrinolysis 1990 (in press)
• 12 Smith P, Arnesen H, Dahl KH, Nilsen DW T, Opstad T, Andersen P. A comparative study of venous occlusion and DDAVP stimulated fibrinolysis in normolipidemic subjects. Thromb Res 1988; 52: 655-660
• 13 Wiman B, Mellbring G, Rånby M. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 1983; 127: 279-288
• 14 Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436
• 15 Bergsdorf N, Nilsson T, Wallen P. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemostas 1983; 50: 740-744
• 16 Declerck PJ, Alessi MC, Verstreken M, Kruithof EK O, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225
• 17 Kaukola S, Manninen V, Mälkönen M, Ehnholm C. Gemfibrozil in the treatment of dyslipidaemia in middle-aged survivors of myocardial infarction. Acta Med Scand 1981; 209: 69-73
• 18 Leren P. The Hypertension – CHD dilemma. Acta Med Scand 1985; 217: 145-147
• 19 Rasi VP O, Torstila I. Effect of gemfibrozil upon platelet function and blood coagulation. Preliminary report. Proc Royal Soc Med 1976; 69 (suppl) (Suppl. 02) 417-419
• 20 Laustiola K, Lassila R, Koskinen P, Peilinen T, Manninen V. Gemfibrozil decreases platelet reactivity in patients with hypercholesterolemia during physical stress. Clin Pharmacol Ther 1988; 43: 302-307
• 21 O“Brien JR, Etherington MD, Shuttleworth RD, Adams CM, Middleton JE, Goodland FC. A pilot study of the effect of gemfibrozil on some haemostatic parameters. Thromb Res 1982; 26: 275-279
• 22 Ciufetti G, Orecchini G, Siepi D, Lupattelli G, Ventura A. Hemorheological activity of gemfibrozil in primary hyperlipidemias. In: Drugs Affecting Lipid Metabolism Paoletti R. et al. (eds) Springer-Verlag; Berlin: 1987. pp 372-375
• 23 Meade TW, Brozovic M, Chakrabarti RR, Haines AP, Imeson JD, Mellows S, Miller GJ, North WR S, Stirling Y, Thompson SG. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 1: 533-537
• 24 Skartlien AH, Lyberg Beckmann S, Holme I, Hjermann I, Prydz H. Effect of alteration in triglyceride levels on factor Vll-phospholipid complexes in plasma. Arteriosclerosis 1989; 9: 798-801
• 25 Brommer EJ P, Gevers Leuven JA, Barrett-Bergshoeff MM, Schouten JA. Response of fibrinolytic activity and factor VUI-related antigen to stimulation with desmopressin in hyperlipoproteinemia. J Lab Clin Med 1982; 100: 105-114
• 26 de Maat MP M, Kluft C, de Boer K, Knot EA R, Jie AF H. Acid treatment of plasma for the inactivation of plasminogen activator inhibitor-1 (PAI-1). Thromb Res 1988; 52: 425-430
• 27 Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
• 28 Nilsson TK, Johnson O. The extrinsic fibrinolytic system in survivors of myocardial infarction. Thromb Res 1987; 48: 621-630
• 29 Huber K, Rose D, Resch I, Schuster E, Glogar DH, Kaindl F, Binder BR. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemostas 1988; 60: 372-376
• 30 Rijken DC. Report of a panel discussion on abnormalities in the t-PA/ PAI system. From the Leiden Fibrinolysis Workshop 2. Fibrinolysis 1988; 2 (suppl) (Suppl. 02) 126-127